Zoetis growth should rebound in 2015, says Argus Argus expects Zoetis' growth to rebound in 2015, as the animal medicine sector moves beyond temporary issues in the U.S. cattle and swine markets. The firm reiterates a Buy rating after the stock underperformed over the past quarter.
Zoetis raises FY15 adjusted EPS view to $1.63-$1.68 from $1.61-$1.68 Consensus $1.66. Raises FY15 revenue view to $4.7B-$4.775B from $4.675B-$4.775B, consensus $4.74B. The company also reaffirmed its long-term outlook for 2016 and 2017.
Zoetis receives conditional license from USDA Zoetis announced that the U.S. Department of Agriculture has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic, an antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. The USDA has communicated that all biological products for canine atopic dermatitis will be considered for conditional licensure only at this time. Zoetis said it is working with the USDA to obtain full licensure.